Recombinant hepatitis B vaccine use in chronic hemodialysis patients

Nephron

Volumn 72, Issue 4, 1996, Pages 536-543

  Fabrizi, F ^a   Di Filippo, S ^a   Marcelli, D ^a   Guarnori, I ^a   Raffaele, L ^a   Crepaldi, M ^a   Erba, G ^a   Locatelli, F ^a  

^a Hospital   (Italy)

Author keywords

Cost effectiveness analysis; Hemodialysis patients; Recombinant hepatitis B vaccine

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; PROTEIN; RECOMBINANT HEPATITIS B VACCINE; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; FEVER; HEMODIALYSIS; HEPATITIS B; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; EVALUATION STUDIES; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; RENAL DIALYSIS; VACCINES, SYNTHETIC;

EID: 0029873521     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188935     Document Type: Article

References (39)

1. Ribot S, Rothstein M, Goldblat M, et al: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 1979:139:178-180.
2. Albertoni F, Battilomo A. Di Nardo V. et al: Evaluation of a region-wide hepatitis vaccination program in dialysis patients: Experience in an Italian region. Nephron 1991:58:180-183.
3. Mioli V. Balestra E. Bibiano E. et al: Epidemiology of viral hepatitis in dialysis centers: A national study. Nephron 1992;61:278-283.
4. Oguchi H, Miyasaka M, Tokunaga S, et al: Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992:38:36-43.
5. Pontcell i C: Prevenzionc dell' epatitc B nei centri dialisi. G It Nefrol 1990:7:7-10.
6. Jilg W, Weincl B, Kutler T. et al: lmmunoge-nicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 1986:3:190-195.
7. Rodby AR. Trcnholme GM: Vaccination of the dialysis patient. Semin Dial 1991:4:102-105.
8. Goudcau A, Coursaget P. Barin F, et al: Prevention of hepatitis B by active and passive-active immunization: in Szmuness W, Alter IIJ. Maynard JE (eds): Viral Hepatitis: 1981 International Symposium. Philadelphia. Franklin Institute Press. 1982. pp 509-525.
9. Buti M. Viladomiu L, Jardi R. et al: Long-term immunogenicitv and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992:12:144-147.
10. Docci D, Cipolloni PA. Mengozzi S, et al: Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: A two year follow-up. Nephron 1992:61:352-354.
11. Dentico P. Zavoianni A. Volpe A. et al: Vaccinazione anti-epatite B negli emodializzati con vaccino ricombinante Engerix-B. Ncfrologia. Dialisi. Trapianto 1990, vol 2. pp 1089-1090.
12. Melappioni M. Baldassari M. Saldini S. et al: Use of immunodulators (Thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic haemodialysis. Nephron 1992:61: 358-359.
13. Ono K. Kashiwagi S: Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991:58:47-51.
14. Marangi AL. Giordano R, Montanaro A. et al: A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992;61:331-332.
15. Milich DR. Thornton GB. Neurath AR. et al: Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985: 228:1195-1199.
16. Rapicetta M: Hepatitis B vaccination in dialysis centres: Advantages and limits. Nephron 1992:61:284-286.
17. Bellavita P. Mattioli L. Andreoletti G. et al: Non responsività alla vaccinazione anti-HBV: valutazione di un nuovo vaccino. Trasf Sang 1992:37:25-28.
18. Centers for Disease Control. Department of Health and Human Services: Update on hepatitis B prevention. Ann Intern Med 1987:107: 353-357.
19. Alter MJ. Favcro MS. Francis DP: Cost benefit of vaccination for hepatitis B in hemodialysis centers (letter). J Infect Dis 1983:148:770-771.
20. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534.
21. Rothman JK: Modern Epidemiology. Boston, Little. Brown, 1986: pp 165-166.
22. Raine AEG. Margrciter R. Brunner FP. et al: Report on management of renal failure in Europe, XXII, 1991, Nephrol Dial Transplant 1992;7(suppl 2): 7-35.
23. Dardanoni L. Bergamini F, Giusti A: Tentativo di elaborazione di un quadro epidemiologico dell' epatite B in Italia. Ig Mod 1983:79:171-197.
24. Caricai P. Bibiano L. Boggi R. et al: HBV infection in haemodialysis patients: Monitoring and prevention. Nephron 1992:61:269-271.
25. Szmuness W, Prince AM. Mann MK. et al: Hepatitis B infection: A point prevalence study in 15 US hemodialysis centers. JAMA 1974: 227:901-906.
26. Fanelli V, Sanna G. Solinas A: Expectation of impaired response to recombinant hepatitis vaccination. Nephron 1992:61:293-295.
27. Dicnstang JL, Werner BG. Polk BF, et al: Hepatitis B vaccine in health care personnel: Safety. immunogenieity and indicators of efficacy. Ann Intern Med 1984:101:34-40.
28. Pozzilli P. Arduini P. Visalli N. et al: Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987:30: 817-819.
29. Sennesael JJ. Van Der Niepen P. Verbcelen DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991;40:121-128.
30. Walz G, Kunzendorf U, Haller H, et al: Factors influencing the response to hepatitis B vaccination of haemodialysis patients. Nephron 1989; 51:474-477.
31. Van Gcelcn JA. Schalm SW. De Visser EM. et al: Immune response to hepatitis B vaccine in hemodialysis patients. Nephron 1987;45:216-218.
32. Stevens CE. Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis: Immunogenieity and efficacy. N Engl J Med 1984;311:496-501.
33. Pasko TM, Bartholomew WR, Beam TR. et al: Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis 1988;11:326-331.
34. Vagelli G. Calabrese G, Mazzotta G, et al: More about response to hepatitis B vaccine in hemodialysis patients (letter). Nephron 1988: 49:171.
35. Stckctcc RW, Ziarnik EM. Davis P: Scrorcs-ponse to hepatitis B vaccine in patients and staff of renal dialysis centers. Wisconsin. Am J Epidemiol 1988;127:772-782.
36. Kamel M. El Manialawi M. De Wolfe Miller F: Recombinant hepatitis B vaccine in presence of hepatitis C virus seropositivity (letter). Lancet 1994:343:552.
37. Gazzola GB, Licenziati M, Perini P, et al: Protocolb regionale per lo studio della risposta alla vaccinazione anti-epatitc B nei donatori di sangue (abstract). Atti XXX Convegno SI1TS-A1CT. 1992. p 553.
38. Lombardi M, Pizzarclli F. Righi M. et al: Hepatitis B vaccination in dialysis patients and nutritional status. Nephron 1992;61:266-268.
39. Hadler SC. Francis DP, Maynard JE. et al: Long-term immunogenieity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986:325:209-214.